SB-649,868

From Wikipedia, the free encyclopedia
  (Redirected from SB649868)
Jump to: navigation, search
SB-649,868
Systematic (IUPAC) name
N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code  ?
PubChem CID 25195495
ChEMBL CHEMBL1272307
Chemical data
Formula C26H24FN3O3S 
Mol. mass 477.549 g/mol (free base)
SMILES eMolecules & PubChem

SB-649,868 is an orexin receptor antagonist in development by GlaxoSmithKline.[1][2] Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573.

[edit] References

  1. ^ Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans". Drug Metabolism and Disposition: the Biological Fate of Chemicals 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199. 
  2. ^ Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R (July 2011). "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist". Journal of Psychopharmacology (Oxford, England). doi:10.1177/0269881111408954. PMID 21730017. 


Personal tools
Namespaces

Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages